Johnson & Johnson (NYSE:JNJ) unit The Janssen Pharmaceutical Companies announces that it will terminate development of antiviral pimodivir for hospitalized influenza A patients.
Its decision was prompted by preliminary data from a Phase 3 clinical trial that showed pimodivir, combined with standard-of-care treatment, was unlikely to show an incremental benefit.
The study and a parallel Phase 3 in outpatients with influenza A will be stopped.
Janssen in-licensed exclusive rights to the drug for influenza A from Vertex Pharmaceuticals (NASDAQ:VRTX) in 2014.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.